Core One Labs Inc. (CLABF)
USD 0.04
(-10.28%)
USD 0.04
(-10.28%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2022 | -15.98 Million CAD | 56.87% |
| 2021 | -37.05 Million CAD | 32.16% |
| 2020 | -54.61 Million CAD | -154.48% |
| 2019 | -21.46 Million CAD | -74.68% |
| 2018 | -12.28 Million CAD | 2.46% |
| 2017 | -12.59 Million CAD | -339.45% |
| 2016 | -2.86 Million CAD | -137.54% |
| 2015 | -1.2 Million CAD | -181.87% |
| 2014 | -428.1 Thousand CAD | 3.1% |
| 2013 | -441.8 Thousand CAD | 3.8% |
| 2012 | -459.22 Thousand CAD | -76.48% |
| 2011 | -260.21 Thousand CAD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 Q1 | -11.97 Million CAD | -329.59% |
| 2023 Q2 | -433.56 Thousand CAD | 96.38% |
| 2023 Q3 | -1.19 Million CAD | -175.52% |
| 2022 FY | -15.98 Million CAD | 56.87% |
| 2022 Q4 | -2.78 Million CAD | -135.78% |
| 2022 Q1 | -11.96 Million CAD | -774.13% |
| 2022 Q2 | -41.17 Thousand CAD | 99.66% |
| 2022 Q3 | -1.18 Million CAD | -2770.76% |
| 2021 FY | -37.05 Million CAD | 32.16% |
| 2021 Q1 | -24.25 Million CAD | 14.51% |
| 2021 Q2 | -5.89 Million CAD | 75.7% |
| 2021 Q3 | -5.53 Million CAD | 6.15% |
| 2021 Q4 | -1.36 Million CAD | 75.26% |
| 2020 Q2 | 486.28 Thousand CAD | 120.38% |
| 2020 Q3 | -24.37 Million CAD | -5111.79% |
| 2020 Q4 | -28.37 Million CAD | -16.43% |
| 2020 FY | -54.61 Million CAD | -154.48% |
| 2020 Q1 | -2.38 Million CAD | 82.16% |
| 2019 Q2 | -3.56 Million CAD | -339.97% |
| 2019 FY | -21.46 Million CAD | -74.68% |
| 2019 Q4 | -13.37 Million CAD | -122.5% |
| 2019 Q1 | 1.48 Million CAD | 137.23% |
| 2019 Q3 | -6.01 Million CAD | -68.71% |
| 2018 Q4 | -3.98 Million CAD | -11.6% |
| 2018 FY | -12.28 Million CAD | 2.46% |
| 2018 Q2 | -2.74 Million CAD | -38.81% |
| 2018 Q1 | -1.97 Million CAD | 69.7% |
| 2018 Q3 | -3.57 Million CAD | -30.08% |
| 2017 Q2 | -879.34 Thousand CAD | -44.41% |
| 2017 Q1 | -608.92 Thousand CAD | 57.97% |
| 2017 Q4 | -6.53 Million CAD | -63.86% |
| 2017 FY | -12.59 Million CAD | -339.45% |
| 2017 Q3 | -3.98 Million CAD | -353.31% |
| 2016 Q2 | -359.15 Thousand CAD | -5.19% |
| 2016 Q3 | -716.89 Thousand CAD | -99.61% |
| 2016 Q4 | -1.44 Million CAD | -102.1% |
| 2016 FY | -2.86 Million CAD | -137.54% |
| 2016 Q1 | -341.44 Thousand CAD | 15.24% |
| 2015 Q2 | -344.02 Thousand CAD | -179.43% |
| 2015 Q4 | -402.83 Thousand CAD | -19.64% |
| 2015 Q3 | -336.69 Thousand CAD | 2.13% |
| 2015 FY | -1.2 Million CAD | -181.87% |
| 2015 Q1 | -123.11 Thousand CAD | 41.48% |
| 2014 Q3 | -118.61 Thousand CAD | -180.36% |
| 2014 Q1 | -56.8 Thousand CAD | 22.15% |
| 2014 Q2 | -42.3 Thousand CAD | 25.52% |
| 2014 FY | -428.1 Thousand CAD | 3.1% |
| 2014 Q4 | -210.37 Thousand CAD | -77.35% |
| 2013 Q2 | -212.29 Thousand CAD | -190.95% |
| 2013 FY | -441.8 Thousand CAD | 3.8% |
| 2013 Q1 | -72.96 Thousand CAD | 2.11% |
| 2013 Q3 | -83.58 Thousand CAD | 60.63% |
| 2013 Q4 | -72.96 Thousand CAD | 12.7% |
| 2012 Q3 | -74.26 Thousand CAD | 13.01% |
| 2012 Q1 | -225.05 Thousand CAD | -1546.31% |
| 2012 FY | -459.22 Thousand CAD | -76.48% |
| 2012 Q2 | -85.37 Thousand CAD | 62.06% |
| 2012 Q4 | -74.53 Thousand CAD | -0.36% |
| 2011 FY | -260.21 Thousand CAD | 0.0% |
| 2011 Q1 | -35.87 Thousand CAD | 0.0% |
| 2011 Q2 | -42.36 Thousand CAD | -18.11% |
| 2011 Q3 | -168.3 Thousand CAD | -297.26% |
| 2011 Q4 | -13.67 Thousand CAD | 91.88% |
| 2010 Q3 | -14.00 CAD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Nuo Therapeutics, Inc. | -3.17 Million USD | -403.93% |
| CNBX Pharmaceuticals Inc. | -3.71 Million USD | -330.75% |
| Mosaic ImmunoEngineering Inc. | -2.38 Million USD | -571.26% |
| Evofem Biosciences, Inc. | 52.97 Million USD | 130.166% |
| GB Sciences, Inc. | -1.36 Million USD | -1073.686% |
| Inhibitor Therapeutics, Inc. | -3.02 Million USD | -428.126% |
| NanoSphere Health Sciences Inc. | -228.12 Thousand USD | -6905.667% |
| Skye Bioscience, Inc. | -37.64 Million USD | 57.546% |
| Zenith Capital Corp. | -10.59 Million USD | -50.829% |
| Agentix Corp. | -1.37 Million USD | -1062.981% |
| Arch Therapeutics, Inc. | -6.98 Million USD | -128.873% |
| Biomind Labs Inc. | -1.21 Million USD | -1216.114% |
| ContraFect Corporation | -65.15 Million USD | 75.47% |
| CSL Limited | 2.64 Billion USD | 100.605% |
| CytoDyn Inc. | -49.84 Million USD | 67.934% |
| GlobeStar Therapeutics Corporation | -1.94 Million USD | -719.896% |
| Neon Bloom, Inc. | -632.4 Thousand USD | -2427.141% |
| Northwest Biotherapeutics, Inc. | -62.59 Million USD | 74.47% |
| ProtoKinetix, Incorporated | -415.47 Thousand USD | -3746.601% |
| Propanc Biopharma, Inc. | -1.82 Million USD | -777.867% |
| Regen BioPharma, Inc. | 1.02 Million USD | 1661.475% |
| Santhera Pharmaceuticals Holding AG | 65.13 Million USD | 124.537% |
| SQZ Biotechnologies Company | -79.46 Million USD | 79.888% |
| Therapeutic Solutions International, Inc. | -2.16 Million USD | -636.552% |
| Eiger BioPharmaceuticals, Inc. | -74.96 Million USD | 78.68% |
| Intellipharmaceutics International Inc. | -2.89 Million USD | -452.546% |
| Mesoblast Limited | -87.95 Million USD | 81.83% |
| Marizyme, Inc. | -65.34 Million USD | 75.543% |
| Genus plc | 7.9 Million USD | 302.302% |
| Pharming Group N.V. | -10.54 Million USD | -51.515% |
| Nymox Pharmaceutical Corporation | -8.84 Million USD | -80.708% |
| RegeneRx Biopharmaceuticals, Inc. | -1.72 Million USD | -825.166% |
| IMV Inc. | -36.48 Million USD | 56.197% |
| AXIM Biotechnologies, Inc. | -8.05 Million USD | -98.293% |
| MultiCell Technologies, Inc. | -380.07 USD | -4204867.243% |
| ONE Bio Corp. | 8.67 Million USD | 284.194% |
| RVL Pharmaceuticals plc | -51.69 Million USD | 69.083% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| Emmaus Life Sciences, Inc. | -3.73 Million USD | -328.123% |
| Provectus Biopharmaceuticals, Inc. | -3.1 Million USD | -415.249% |
| Oncotelic Therapeutics, Inc. | -7.9 Million USD | -102.222% |
| THC Farmaceuticals, Inc. | -14.97 Thousand USD | -106616.206% |
| Acro Biomedical Co., Ltd. | -15.87 Million USD | -0.695% |
| Alpha Cognition Inc. | -13.77 Million USD | -16.041% |
| Enzolytics Inc. | -2.17 Million USD | -634.178% |
| MetaStat, Inc. | - USD | Infinity% |
| argenx SE | -295.05 Million USD | 94.583% |
| Enzon Pharmaceuticals, Inc. | 98 Thousand USD | 16407.979% |
| Endonovo Therapeutics, Inc. | 6.92 Million USD | 330.798% |
| Genscript Biotech Corporation | -95.47 Million USD | 83.261% |
| Nanobac Pharmaceuticals, Incorporated | -6.57 Million USD | -143.028% |
| Institute of Biomedical Research Corp. | -273.4 Thousand USD | -5745.538% |
| Sigyn Therapeutics, Inc. | -4.14 Million USD | -285.482% |
| WPD Pharmaceuticals Inc. | -60.44 Thousand USD | -26342.187% |
| Cotinga Pharmaceuticals Inc. | -2 Million USD | -697.052% |
| VioQuest Pharmaceuticals, Inc. | -10.89 Million USD | -46.733% |
| PsyBio Therapeutics Corp. | -4.88 Million USD | -227.09% |
| Adynxx, Inc. | - USD | Infinity% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| Accustem Sciences Inc. | -3.74 Million USD | -326.589% |
| Helix BioMedix, Inc. | -1.05 Million USD | -1413.348% |
| EV Biologics, Inc. | -1.26 Million USD | -1161.257% |
| Q BioMed Inc. | -2.05 Million USD | -678.806% |
| Capstone Therapeutics Corp. | -3.81 Million USD | -318.482% |
| American Oriental Bioengineering, Inc. | -59.72 Million USD | 73.241% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| BioStem Technologies, Inc. | -8.48 Million USD | -88.399% |
| Curative Biotechnology, Inc. | -5.81 Million USD | -174.731% |
| HST Global, Inc. | -146.21 Thousand USD | -10830.729% |
| Burzynski Research Institute, Inc. | -1.33 Million USD | -1096.754% |
| Wesana Health Holdings Inc. | -1.75 Million USD | -810.764% |
| Halberd Corporation | -79.67 Thousand USD | -19958.511% |
| Resverlogix Corp. | -3.61 Million USD | -342.71% |
| Cell Source, Inc. | -5.32 Million USD | -200.342% |
| RespireRx Pharmaceuticals Inc. | -3.97 Million USD | -302.261% |
| GeneThera, Inc. | - USD | Infinity% |
| AVAX Technologies, Inc. | -6.41 Million USD | -149.185% |
| Ember Therapeutics, Inc. | -23.24 Thousand USD | -68662.667% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| NovAccess Global Inc. | -4.76 Million USD | -235.106% |
| Kadimastem Ltd | -3.3 Million USD | -383.214% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Rasna Therapeutics, Inc. | -4.44 Million USD | -259.745% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | -441.36 Thousand USD | -3520.965% |
| LadRx Corporation | 400.44 Thousand USD | 4091.035% |
| Regen BioPharma, Inc. | 1.02 Million USD | 1661.475% |
| Affymax, Inc. | -14.42 Million USD | -10.8% |
| Itoco Inc. | -1.86 Million USD | -755.102% |
| Pathfinder Cell Therapy, Inc. | -1.66 Million USD | -857.569% |
| Mobile Lads Corp. | -2.26 Million USD | -606.132% |
| International Stem Cell Corporation | -131 Thousand USD | -12099.862% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| Bioxytran, Inc. | -4.28 Million USD | -273.407% |
| NDT Pharmaceuticals Inc. | -79.03 Thousand USD | -20121.704% |
| Qrons Inc. | -789.34 Thousand USD | -1924.689% |
| Alseres Pharmaceuticals, Inc. | -941.52 Thousand USD | -1597.432% |
| SYBLEU INC | -180.3 Thousand USD | -8763.818% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| Nascent Biotech, Inc. | -2.08 Million USD | -665.529% |
| Rebus Holdings, Inc. | -1.02 Million USD | -1466.845% |
| ImmunoCellular Therapeutics, Ltd. | -1.61 Million USD | -890.975% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -54.27 Thousand USD | -29347.632% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -2.53 Million USD | -531.631% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -48.07 Million USD | 66.754% |
| Adhera Therapeutics, Inc. | -2.11 Million USD | -655.999% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -780.88 Thousand USD | -1946.624% |
| Innovation Pharmaceuticals Inc. | -3.16 Million USD | -404.477% |
| Neutra Corp. | -233.46 Thousand USD | -6745.488% |
| Windtree Therapeutics, Inc. | -20.29 Million USD | 21.237% |
| PureTech Health plc | -65.69 Million USD | 75.673% |
| Coeptis Therapeutics, Inc. | -21.26 Million USD | 24.85% |
| IXICO plc | -1.17 Million USD | -1256.691% |
| IntelGenx Technologies Corp. | -9.92 Million USD | -60.993% |
| Gelesis Holdings, Inc. | -57.12 Million USD | 72.025% |
| CSL Limited | 2.64 Billion USD | 100.605% |
| Cellectis S.A. | -103.17 Million USD | 84.51% |